Electronic letter

Screening families with endometrial and colorectal cancers for germline mutations

Tao Liu, Jindong Chen, Sima Salahshor, Shannon Kuismanen, Eva Holmberg, Henrik Grönberg, Päivi Peltomäki, Annika Lindblom

Department of
Molecular Medicine,
Clinical Genetics Unit,
CMM L8-0:2
Karolinska Institutet,
S-171 76 Stockholm,
Sweden
T Liu
J Chen
S Salahshor
A Lindblom

Department of
Medical Genetics,
Haartman Institute,
University of Helsinki,
00290
Haartmaninkatu,
Helsinki, Finland
S Kuismanen

Department of Clinical
Genetics, University
Hospital, S-901 85
Umeå, Sweden
E Holmberg

Department of
Oncology, University
Hospital, S-901 85
Umeå, Sweden
H Grönberg

Human Cancer
Genetics,
Comprehensive
Cancer Center, Ohio
State University,
Columbus, Ohio 43210,
USA
P Peltomäki

Correspondence to:
Dr Lindblom,
annika.lindblom@cmm.ki.se

EDITOR—Endometrial cancer is the most commonly diagnosed cancer of the female reproductive tract in the United States and other western countries.¹ Although several genes may be altered in these cancers,² the molecular events in the development of endometrial carcinoma remain poorly defined. Changes in simple sequence repeats in tumour DNA relative to normal DNA, referred to as microsatellite instability (MSI), are a feature of many endometrial carcinomas.^{3–7} MSI occurs as a result of failing DNA mismatch repair⁸ and is known to accompany defects in the *MLH1*, *MSH2*, *MSH6*, *MSH3*, *PMS2*, and possibly *PMS1* genes. Apart from *MSH3*, all these genes are associated with inherited cancer susceptibility in the context of hereditary non-polyposis colorectal cancer (HNPCC).^{9–16} Endometrial carcinomas are the most common extracolonic cancers in HNPCC¹⁷ and usually occur at an early age.¹⁸ Women who carry HNPCC mutations have a 22–43% lifetime risk of developing endometrial cancer as compared with 3% for the general population.^{19–21} According to a recent report, germline mutations of the DNA mismatch repair gene *MSH6* might be specifically associated with susceptibility to endometrial cancer.²²

PTEN is a newly isolated tumour suppressor gene located on chromosome 10q23, a region frequently deleted in multiple types of human cancer.^{23–25} Inactivation of *PTEN* is the underlying cause of familial Cowden disease.²⁶ Inactivating mutations in the *PTEN* gene are frequently found in multiple tumour types including brain, breast, prostate, endometrial, and skin carcinomas.^{23–25} Knockout mice for *PTEN* die as early embryos, while animals heterozygous for a mutant *PTEN* allele develop a broad spectrum of tumours.^{27–29} These observations have established that *PTEN* has multiple target organs including the endometrium.

Recent reports have shown that β -catenin is a multifunctional protein involved in two apparently independent processes. In one it acts as a cell adhesion regulator when coupled with E-cadherin.³⁰ In the other it acts as an oncogene in the wingless/Wnt signal transduction pathway.³¹ The Wnt pathway is highly conserved, and phosphorylation of specific Ser/Thr residues of β -catenin by serine-threonine glycogen synthase kinase (GSK)- β is a key step in the ubiquitin mediated

degradation of β -catenin. Mutation of the APC protein causes an increase in the β -catenin protein, resulting in activation of the Wnt signalling pathway.³² Hence, structural alterations of the GSK- β phosphorylation sites of β -catenin would also cause activation of the Wnt pathway. In fact, mutations of *β -catenin* involving specific Ser/Thr sites in exon 3 were observed in a variety of tumours especially in endometrial and colorectal cancers without APC mutations.^{33–35} Mutation rates of 11–45% have been reported for exon 3 of *β -catenin* in endometrial cancer irrespective of MSI status.^{36–38}

The purpose of this study was to explore the genetic basis of familial endometrial cancer in 10 families available to us. If susceptibility to endometrial cancer were associated with defective MMR, or inactivation of a tumour suppressor gene or activation of an oncogene, a heritable mutation in one of these genes would be expected to be present. To test this hypothesis, a comprehensive mutation analysis of the MMR genes *MLH1*, *MSH2*, *PMS1*, *PMS2*, *MSH3*, and *MSH6*, the tumour suppressor gene *PTEN*, and exon 3 of *β -catenin* was undertaken in these families.

Materials and methods

PATIENTS

A total of 10 women with endometrial cancer were studied. Three were from families in which endometrial cancer alone seemed to segregate as an autosomal dominant trait, four were from HNPCC families meeting the modified Amsterdam criteria,³⁹ and the remaining three with endometrial and colorectal cancer did not fit either classification. The patients were recruited through the Cancer Family Clinic at Karolinska Hospital and the Umeå University Hospital between 1990 and 1996.

SCREENING FOR GERMLINE MUTATIONS

DGGE/CDGE

DNA was extracted from whole blood according to routine procedures. *MLH1* and *MSH2* were screened for mutations by denaturing gradient gel electrophoresis (DGGE).^{40,41} *MSH2* exon 5 was studied by constant denaturing gel electrophoresis (CDGE) as described previously.⁴² Alterations identified by DGGE/CDGE were verified by sequencing of genomic DNA.

Figure 1 Pedigrees of families included in present study. Filled symbols indicate endometrial cancer (E), colon cancer (Co), rectal cancer (Re), ovarian cancer (Ov), bladder cancer (Bl), glioma (Gi), gastric cancer (Ga), lung cancer (L), and sarcoma (S). The number below each symbol indicates the age at diagnosis. Arrows indicate probands.

RT-PCR/PTT

RNA was extracted from EBV cell lines using the Ultraspec-II RNA PCR kit (Perkin Elmer, Foster City, CA). The random hexamer priming method was used with the GeneAmp RNA PCR kit (Perkin Elmer, Foster City, CA) to synthesise cDNA. The protein truncation test (PTT) was carried out according to the manufacturer's instructions (Promega). The cDNA was amplified in two overlapping fragments for *MLH1*, *MSH2*, *MSH3*, *MSH6*, and *PMS2*^{12 43 44} and in three fragments for *PMS1*.¹² The *PTEN* cDNA was amplified in two fragments using primers published previously.⁴⁵ Alterations identified by RT-PCR/PTT were verified by sequencing of cDNA and genomic DNA.

Direct sequencing of *MSH6* and β -catenin

The individual exons and flanking intron sequences of *MSH6* were amplified using primers and cycling conditions described previously.⁴⁶ Exon 3 of β -catenin was studied as described previously.⁴⁷ Fifty ng of genomic DNA were amplified in each reaction under the following conditions: one cycle of 96°C for two minutes, 35 cycles of 94°C for 30 seconds, 55°C for 45 seconds, and 72°C for one minute,

and one cycle of 72°C for 10 minutes. The PCR product was purified using Microcolumn (Amicon). Fifty ng of the PCR product was sequenced using internal primers,⁴⁷ Thermo

Figure 2 A *MSH2* germline mutation detected by DGGE. Lane 1, marker; lane 2, index patient of family 82; lanes 3–4, normal and tumour DNA from the son of the index patient; lane 5, normal control.

Figure 3 Genomic DNA sequencing for family 82. The index patient was heterozygous for a TCT deletion in *MSH2* (left) while the son of the index patient (middle) and a normal control (right) showed the wild type sequence.

Sequenase (Amersham Corp), and ^{33}P -labelled ddNTPs (Amersham) according to the manufacturer's instructions. Single base substitutions in exons 2 and 3 of *MSH6* found by direct sequencing were further investigated in newly collected samples and in normal controls by specific variant detection techniques. Primer sequences and PCR conditions are available from the authors upon request.

MSI analysis

A previous study showed that mononucleotide markers are much more sensitive in identifying MSI as compared to dinucleotide markers⁴⁸; in fact, BAT-26 alone has been suggested to be sufficient for diagnosis of microsatellite instability.⁴⁹ Tumour analysis was therefore performed with two mononucleotide repeat markers, BAT-25 and BAT-26, and the tumours were considered MSI-H if both markers showed sequence alterations.⁵⁰ If only one of BAT-25 or BAT-26 was positive, a panel of 10 dinucleotide markers (D3S1283, D3S647, D3S1514, D2S119, D2S147, LNSCA1 (*APC*), *TP53*, D3S1029, D3S1611, D3S1298) was studied as previously described⁵¹ and

tumours with mutations in more than 40% of informative markers were considered MSI-H.⁵²

Results and discussion

Ten women with endometrial cancer were screened for germline mutations in eight different genes. *MLH1* and *MSH2* were first evaluated by DGGE on genomic DNA, followed by RT-PCR and PTT on cDNA. The cDNA sequences of *PTEN*, *PMS1*, *PMS2*, *MSH3*, and *MSH6* were investigated by RT-PCR and PTT; additionally, *MSH6* exons and flanking introns were sequenced from genomic DNA. β -catenin exon 3 was studied by direct sequencing of genomic DNA. The mutation screening strategy chosen should allow the detection of most pathogenic alterations in the MMR and tumour suppressor genes studied, with the exception of possible mutations in the promoter or 3' untranslated region.

DGGE and sequence analysis showed a germline mutation in *MSH2* (in frame deletion of bases 279 to 281 of exon 2) in a woman with endometrial cancer from family 82 (figs 1, 2, and 3, table 1). The index patient was 75 years old and had a son affected with colon cancer at 49 years of age. The endometrial cancer of the index patient was MSI negative, while the colon cancer of her son was MSI positive. Segregation analysis showed that the son, despite having an MSI positive colon cancer at a young age, did not have the *MSH2* mutation. Furthermore, the alteration was not observed in 142 HNPCC families or families with a history of colorectal cancer.⁵³ We conclude that this mutation was not associated with colon cancer and it remains unclear whether it was important in the development of endometrial cancer in this family.

Two single base substitutions in *MSH6* were identified (families 154 and 106 in table 1). Both alterations have been published as non-pathogenic polymorphisms.^{54 55} Interestingly, the index patients of these two families harboured both variants. To evaluate the pathogenicity of these variants, we analysed 30 patients with a family history of endometrial or

Table 1 Characteristics of 10 endometrial cancer and endometrial/colorectal cancer families and mutation screening results

Fam No	Tumour type	MSI status	Mutation screening							β -catenin sequencing of exon 3
			<i>MLH1</i> DGGE/PTT	<i>MSH2</i> DGGE/PTT	<i>MSH3</i> PTT	<i>MSH6</i> PTT/sequencing	<i>PMS1</i> PTT	<i>PMS2</i> PTT	<i>PTEN</i> PTT	
154	3 EC*	-†	-/-	-/-	-	-/pm‡	-	-	-	-
73	4 EC+Gi	ND §	-/-	-/-	-	-/-	-	-	-	-
54	4 EC	ND	-/-	-/-	-	-/-	-	-	-	-
121	2 EC+1 CRC¶	-	-/-	-/-	-	-/-	-	-	-	-
53	3 EC+3 CRC	-	-/-	-/-	-	-/-	-	-	-	-
147	1 EC+1 CRC	-	-/-	-/-	-	-/-	-	-	-	-
128	1 EC+4 CRC	-	-/-	-/-	-	-/-	-	-	-	-
60	1 EC+3 CRC	-	-/-	-/-	-	-/-	-	-	-	-
106	1 EC+4 CRC	ND	-/-	pm **/-	-	-/pm ††	-	-	-	-
82	1 EC+1 CRC	-	-/-	mut ‡‡/-	-	-/-	-	-	-	-

*Endometrial cancer.

†MSI analysis and mutation screening was negative.

‡Polymorphism was CCA→CCG (Pro→Pro) at 276 of exon 2, and GAT→GAC (ASP→ASP) at 540 in *MSH6*.

§MSI analysis was not done.

¶Colorectal cancer.

**Polymorphism was C→G (Ala→Ala) at 984 of exon 6 in *MSH2*.

††Polymorphism was CCA→CCG (Pro→Pro) at 276 of exon 2, and GAT→GAC (ASP→ASP) at 540 in *MSH6*.

‡‡Mutation was del TCT at 279–281 of exon 3 in *MSH2*.

colorectal cancer and 192 anonymous normal controls. Variant CCA→CCG (Pro→Pro) at codon 92 was found in 24% of the patients and 23.5% of normal controls, while variant GAT→GAC (Asp→Asp) was identified in 41% of the patients and 44% of normal controls. We also investigated the coexistence of these variants and found no statistically significant difference between the numbers of subjects with compound variants among our cases (7/30, 23%) and controls (23/192, 12%). The comparable frequencies observed in the patients and controls suggested that these variants were likely to be harmless polymorphisms. Finally, *PTEN* and β -catenin showed no germline mutations in this subset of endometrial cancer or endometrial and colorectal cancer families.

All available endometrial tumours (one tumour from seven families each) were MSI negative, including the tumour that harboured a germline mutation in *MSH2* described above. Endometrial tumours from HNPCC families are typically MSI positive.^{3 16 22} Our finding of MSI negative tumours together with the lack of germline mutations in MMR genes suggests a non-significant role for these genes in the present relatively limited series of families with endometrial cancer. Even though the actual genes predisposing to endometrial and colorectal cancer in these families remain to be identified, the possibility of an increased cancer risk owing to inherited susceptibility should be considered in the counselling of such families.

- We recruited 10 families affected by either endometrial cancer alone or with both endometrial and colorectal cancer and carried out mutation screening of six MMR genes (*MLH1*, *MSH2*, *MSH3*, *MSH6*, *PMS1*, and *PMS2*). We also investigated the whole coding sequence of *PTEN* and a specific mutable site of β -catenin. No germline mutation with a clear pathogenic role was identified in any of the genes studied.
- Seven available endometrial tumours from the present families were MSI negative indicating that efficient mismatch repair was maintained in these tumours.
- The lack of clear cut pathogenic germline mutations of MMR genes suggests a limited role for these genes in familial endometrial cancer and implies that as yet unknown susceptibility genes are likely to be involved in such families.

We are indebted to the families included in this study. The project was supported by the Swedish Cancer Society, the Cancer Foundation in Stockholm, Centrala Försöksdjursnämnden, and the European Commission (BMH4-CT96-0772), the Sigrid Juselius Foundation, the Academy of Finland, and the National Institute of Health grants CA 82282 and P30 CA 16058.

- 1 Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998 (published errata appear in *CA Cancer J Clin* 1998;48:192, 329). *CA Cancer J Clin* 1998;48:6-29.

- 2 Burton JL, Wells M. Recent advances in the histopathology and molecular pathology of carcinoma of the endometrium. *Histopathology* 1998;33:297-303.
- 3 Risinger JI, Berchuck A, Kohler MF, Watson P, Lynch HT, Boyd J. Genetic instability of microsatellites in endometrial carcinoma. *Cancer Res* 1993;53:5100-3.
- 4 Peiffer SL, Herzog TJ, Tribune DJ, Mutch DG, Gersell DJ, Goodfellow PJ. Allelic loss of sequences from the long arm of chromosome 10 and replication errors in endometrial cancers. *Cancer Res* 1995;55:1922-6.
- 5 Burks RT, Kessiss TD, Cho KR, Hedrick L. Microsatellite instability in endometrial carcinoma. *Oncogene* 1994;9:1163-6.
- 6 Duggan BD, Felix JC, Muderspach LI, Tourgeman D, Zheng J, Shibata D. Microsatellite instability in sporadic endometrial carcinoma. *J Natl Cancer Inst* 1994;86:1216-21.
- 7 Kobayashi K, Sagae S, Kudo R, Saito H, Koi S, Nakamura Y. Microsatellite instability in endometrial carcinomas: frequent replication errors in tumors of early onset and/or of poorly differentiated type. *Genes Chrom Cancer* 1995;14:128-32.
- 8 Parsons R, Li GM, Longley MJ, Fang WH, Papadopoulos N, Jen J, de la Chapelle A, Kinzler KW, Vogelstein B, Modrich P. Hypermutability and mismatch repair deficiency in RER+ tumor cells. *Cell* 1993;75:1227-36.
- 9 Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, Garber J, Kane M, Kolodner R. The human mutator gene homolog *MSH2* and its association with hereditary nonpolyposis colon cancer (published erratum appears in *Cell* 1994;77:167). *Cell* 1993;75:1027-38.
- 10 Leach FS, Nicolaides NC, Papadopoulos N, Liu B, Jen J, Parsons R, Peltomäki P, Sistonen P, Aaltonen LA, Nyström-Lahti M, Guan XY, Zhang J, Meltzer PS, Yu JW, Kao FT, Chen DJ, Cerosaletti KM, Fournier REK, Todd S, Lewis T, Leach RJ, Naylor SL, Weissbach J, Mecklin JP, Järvinen H, Petersen GM, Hamilton SR, Green J, Jass J, Watson P, Lynch HT, Trent JM, de la Chapelle A, Kinzler KW, Vogelstein B. Mutations of a *mutS* homolog in hereditary nonpolyposis colon cancer. *Cell* 1993;75:1215-25.
- 11 Papadopoulos N, Nicolaides NC, Wei YF, Ruben SM, Carter KC, Rosen CA, Haseltine WA, Fleischmann RD, Fraser CM, Adams MD, Venter JC, Hamilton SR, Petersen GM, Watson P, Lynch HT, Peltomäki P, Mecklin JP, de la Chapelle A, Kinzler KW, Vogelstein B. Mutation of a *mutL* homolog in hereditary colon cancer. *Science* 1994;263:1625-9.
- 12 Nicolaides NC, Papadopoulos N, Liu B, Wei YF, Carter KC, Ruben SM, Rosen CA, Haseltine WA, Fleischmann RD, Fraser CM, Adams MD, Venter JC, Dunlop MG, Hamilton SR, Petersen GM, de la Chapelle A, Vogelstein B, Kinzler KW. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. *Nature* 1994;371:75-80.
- 13 Palombo F, Gallinari P, Iaccarino I, Lettieri T, Hughes M, D'Arrigo A, Truong O, Hsuan JJ, Jiricny J. GTBP, a 160-kilodalton protein essential for mismatch-binding activity in human cells. *Science* 1995;268:1912-14.
- 14 Miyaki M, Konishi M, Tanaka K, Kikuchi-Yanoshita R, Muraoka M, Yasuno M, Igari T, Koike M, Chiba M, Mori T. Germline mutation of *MSH6* as the cause of hereditary nonpolyposis colorectal cancer. *Nat Genet* 1997;17:271-2.
- 15 Watanabe A, Ikejima M, Suzuki N, Shimada T. Genomic organization and expression of the human *MSH3* gene. *Genomics* 1996;31:311-18.
- 16 Aaltonen LA, Peltomäki P, Mecklin JP, Järvinen H, Jass JR, Green JS, Lynch HT, Watson P, Tallqvist G, Juhola M, Sistonen P, Hamilton SR, Kinzler KW, Vogelstein B, de la Chapelle A. Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. *Cancer Res* 1994;54:1645-8.
- 17 Mecklin JP, Järvinen HJ. Tumor spectrum in cancer family syndrome (hereditary nonpolyposis colorectal cancer). *Cancer* 1991;68:1109-12.
- 18 Hakala T, Mecklin JP, Forss M, Järvinen H, Lehtovirta P. Endometrial carcinoma in the cancer family syndrome. *Cancer* 1991;68:1656-9.
- 19 Watson P, Lynch HT. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. *Cancer* 1993;71:677-85.
- 20 Aarnio M, Mecklin JP, Aaltonen LA, Nyström-Lahti M, Järvinen HJ. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. *Int J Cancer* 1995;64:430-3.
- 21 Dunlop MG, Farrington SM, Carothers AD, Wyllie AH, Sharp L, Burn J, Liu B, Kinzler KW, Vogelstein B. Cancer risk associated with germline DNA mismatch repair gene mutations. *Hum Mol Genet* 1997;6:105-10.
- 22 Wijnen J, de Leeuw W, Vasen H, van der Klift H, Moller P, Stormorken A, Meijers-Heijboer H, Lindhout D, Menko F, Vossen S, Moslein G, Tops C, Brocker-Vriends A, Wu Y, Hofstra R, Sijmons R, Cornelisse C, Morreau H, Fodde R. Familial endometrial cancer in female carriers of *MSH6* germline mutations. *Nat Genet* 1999;23:142-4.
- 23 Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R. *PTEN*, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. *Science* 1997;275:1943-7.
- 24 Li DM, Sun H. *TEP1*, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. *Cancer Res* 1997;57:2124-9.

- 25 Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH, Tavtigian SV. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. *Nat Genet* 1997;15:356-62.
- 26 Eng C, Peacocke M. PTEN and inherited hamartoma-cancer syndromes. *Nat Genet* 1998;19:223.
- 27 Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. Pten is essential for embryonic development and tumour suppression. *Nat Genet* 1998;19:348-55.
- 28 Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP, Mak TW. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. *Cell* 1998;95:29-39.
- 29 Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM, Cordon-Cardo C, Catoretti G, Fisher PE, Parsons R. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. *Proc Natl Acad Sci USA* 1999;96:1563-8.
- 30 Hulsken J, Birchmeier W, Behrens J. E-cadherin and APC compete for the interaction with beta-catenin and the cytoskeleton. *J Cell Biol* 1994;127:2061-9.
- 31 Gumbiner BM. Signal transduction of beta-catenin. *Curr Opin Cell Biol* 1995;7:634-40.
- 32 Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, Vogelstein B, Clevers H. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. *Science* 1997;275:1784-7.
- 33 Iwao K, Nakamori S, Kameyama M, Imaoka S, Kinoshita M, Fukui T, Ishiguro S, Nakamura Y, Miyoshi Y. Activation of the beta-catenin gene by interstitial deletions involving exon 3 in primary colorectal carcinomas without adenomatous polyposis coli mutations. *Cancer Res* 1998;58:1021-6.
- 34 Sparks AB, Morin PJ, Vogelstein B, Kinzler KW. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. *Cancer Res* 1998;58:1130-4.
- 35 Palacios J, Gamallo C. Mutations in the beta-catenin gene (CTNNB1) in endometrioid ovarian carcinomas. *Cancer Res* 1998;58:1344-7.
- 36 Mirabelli-Primdahl L, Gryfe R, Kim H, Millar A, Luceri C, Dale D, Holowaty E, Bapat B, Gallinger S, Redston M. Beta-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway. *Cancer Res* 1999;59:3346-51.
- 37 Kobayashi K, Sagae S, Nishioka Y, Tokino T, Kudo R. Mutations of the beta-catenin gene in endometrial carcinomas. *Jpn J Cancer Res* 1999;90:55-9.
- 38 Ikeda T, Yoshinaga K, Semba S, Kondo E, Ohmori H, Horii A. Mutational analysis of the CTNNB1 (beta-catenin) gene in human endometrial cancer: frequent mutations at codon 34 that cause nuclear accumulation. *Oncol Rep* 2000;7:323-6.
- 39 Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. *Gastroenterology* 1999;116:1453-6.
- 40 Tannergard P, Lipford JR, Kolodner R, Frodin JE, Nordenskjold M, Lindblom A. Mutation screening in the hMLH1 gene in Swedish hereditary nonpolyposis colon cancer families. *Cancer Res* 1995;55:6092-6.
- 41 Wahlberg SS, Nystrom-Lahti M, Kane MF, Kolodner RD, Peltomaki P, Lindblom A. Low frequency of hMSH2 mutations in Swedish HNPCC families. *Int J Cancer* 1997;74:134-7.
- 42 Borresen AL, Lothe RA, Meling GI, Lystad S, Morrison P, Lipford J, Kane MF, Rognum TO, Kolodner RD. Somatic mutations in the hMSH2 gene in microsatellite unstable colorectal carcinomas. *Hum Mol Genet* 1995;4:2065-72.
- 43 Holmberg M, Kristo P, Chadwick RB, Mecklin JP, Jarvinen H, de la Chapelle A, Nystrom-Lahti M, Peltomaki P. Mutation sharing, predominant involvement of the MLH1 gene and description of four novel mutations in hereditary nonpolyposis colorectal cancer. Mutations in brief no 144. Online. *Hum Mutat* 1998;11:482.
- 44 Percesepe A, Kristo P, Aaltonen LA, Ponz de Leon M, de la Chapelle A, Peltomaki P. Mismatch repair genes and mononucleotide tracts as mutation targets in colorectal tumors with different degrees of microsatellite instability. *Oncogene* 1998;17:157-63.
- 45 Chen J, Lindblom P, Lindblom A. A study of the PTEN/MMAC1 gene in 136 breast cancer families. *Hum Genet* 1998;102:124-5.
- 46 Kolodner RD, Tytell JD, Schmeits JL, Kane MF, Gupta RD, Weger J, Wahlberg S, Fox EA, Peel D, Ziogas A, Garber JE, Syngal S, Anton-Culver H, Li FP. Germ-line msh6 mutations in colorectal cancer families. *Cancer Res* 1999;59:5068-74.
- 47 Kitaeva MN, Grogan L, Williams JP, Dimond E, Nakahara K, Hausner P, DeNobile JW, Soballe PW, Kirsch IR. Mutations in beta-catenin are uncommon in colorectal cancer occurring in occasional replication error-positive tumors. *Cancer Res* 1997;57:4478-81.
- 48 Zhou XP, Hoang JM, Cottu P, Thomas G, Hamelin R. Allelic profiles of mononucleotide repeat microsatellites in control individuals and in colorectal tumors with and without replication errors. *Oncogene* 1997;15:1713-18.
- 49 Hoang JM, Cottu PH, Thuille B, Salmon RJ, Thomas G, Hamelin R. BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines. *Cancer Res* 1997;57:300-3.
- 50 Perucho M. Correspondence re Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava S. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. (*Cancer Res* 1998;58:5248-57.) *Cancer Res* 1999;59:249-56.
- 51 Tannergard P, Liu T, Weger A, Nordenskjold M, Lindblom A. Tumorigenesis in colorectal tumors from patients with hereditary non-polyposis colorectal cancer. *Hum Genet* 1997;101:51-5.
- 52 Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava S. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. *Cancer Res* 1998;58:5248-57.
- 53 Wahlberg S, Liu T, Lindblom P, Lindblom A. Various mutation screening techniques in the DNA mismatch repair genes hMSH2 and hMLH1. *Genet Test* 1999;3:259-64.
- 54 Kolodner RD, Tytell JD, Schmeits JL, Kane MF, Gupta RD, Weger J, Wahlberg S, Fox EA, Peel D, Ziogas A, Garber JE, Syngal S, Anton-Culver H, Li FP. Germ-line msh6 mutations in colorectal cancer families. *Cancer Res* 1999;59:5068-74.
- 55 Charaimes GS, Millar AL, Pal T, Narod S, Bapat B. Do MSH6 mutations contribute to double primary cancers of the colorectum and endometrium? *Hum Genet* 2000;107:623-9.